Generic Name: islatravir

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

Company: Merck & Company

Approval Status: Experimental

Generic Version Available: No

Experimental Code: MK-8591

Drug Indication

Islatravir is an investigational drug being studied to treat and prevent HIV. It has not yet been approved by the Food and Drug Administration or reviewed for inclusion in the DHHS list of recommended medications for HIV treatment or prevention.

General Info

Islatravir belongs to a group of HIV drugs called nucleoside reverse transcriptase translocation inhibitors. It may be effective against certain HIV strains that are resistant to other drugs.

Islatravir is currently in Phase III development for HIV treatment. It is being studied as a single-drug capsule and as part of a fixed-dose combination containing doravirine and islatravir. It is also being studied as part of a once-weekly treatment regimen with another experimental drug. 

Oral islatravir is also being studied as a once-monthly pre-exposure prophylaxis (PrEP) option. In implantable formulation of the drug may prevent HIV for as long as a year.


Dosing Info: N/A

Side Effects

In clinical trials, the most commonly reported side effects among participants who took islatravir were headache, nausea, vomiting, diarrhea and joint pain.

Other Info

Click here for more info on Islatravir.

Last Reviewed: December 30, 2020